Tyche Wealth Partners LLC purchased a new stake in Eli Lilly and Company (NYSE:LLY – Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,086 shares of the company’s stock, valued at approximately $1,799,000.
Several other institutional investors and hedge funds also recently made changes to their positions in LLY. JGP Wealth Management LLC increased its stake in shares of Eli Lilly and Company by 0.9% in the fourth quarter. JGP Wealth Management LLC now owns 1,843 shares of the company’s stock worth $1,074,000 after purchasing an additional 16 shares in the last quarter. Cassia Capital Partners LLC grew its stake in Eli Lilly and Company by 1.8% during the third quarter. Cassia Capital Partners LLC now owns 951 shares of the company’s stock valued at $511,000 after acquiring an additional 17 shares in the last quarter. Walkner Condon Financial Advisors LLC grew its stake in Eli Lilly and Company by 2.8% during the third quarter. Walkner Condon Financial Advisors LLC now owns 621 shares of the company’s stock valued at $334,000 after acquiring an additional 17 shares in the last quarter. Patton Albertson Miller Group LLC grew its stake in Eli Lilly and Company by 2.8% during the third quarter. Patton Albertson Miller Group LLC now owns 623 shares of the company’s stock valued at $335,000 after acquiring an additional 17 shares in the last quarter. Finally, Valley Wealth Managers Inc. grew its stake in Eli Lilly and Company by 1.3% during the third quarter. Valley Wealth Managers Inc. now owns 1,280 shares of the company’s stock valued at $688,000 after acquiring an additional 17 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.
Eli Lilly and Company Stock Performance
Shares of LLY stock traded down $4.21 during trading hours on Tuesday, reaching $746.56. The company had a trading volume of 2,569,130 shares, compared to its average volume of 3,085,273. The business has a fifty day moving average price of $762.68 and a 200-day moving average price of $655.54. Eli Lilly and Company has a one year low of $367.35 and a one year high of $800.78. The firm has a market cap of $709.35 billion, a PE ratio of 128.34, a price-to-earnings-growth ratio of 1.65 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94.
Insider Buying and Selling
In related news, major shareholder Lilly Endowment Inc sold 78,573 shares of the firm’s stock in a transaction that occurred on Wednesday, January 31st. The shares were sold at an average price of $648.07, for a total value of $50,920,804.11. Following the transaction, the insider now owns 99,333,810 shares of the company’s stock, valued at $64,375,262,246.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.13% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
Several brokerages recently commented on LLY. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Barclays boosted their price objective on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a research note on Wednesday, February 7th. The Goldman Sachs Group boosted their price target on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Cantor Fitzgerald reissued an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a research note on Monday. Finally, Truist Financial reissued a “buy” rating and issued a $850.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 22nd. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.
Read Our Latest Analysis on LLY
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Featured Articles
- Five stocks we like better than Eli Lilly and Company
- 3 Tickers Leading a Meme Stock Revival
- Silicon Motion Proves That AI in Motion Stays in Motion
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Undervalued UnitedHealth Group Won’t Be For Long
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- The 5 Stocks Most Sold By Insiders This Year
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY – Free Report).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.